Research programme: irritable bowel syndrome therapy - Melior DiscoveryAlternative Names: MLR-1045
Latest Information Update: 16 Jul 2016
Price : $50 *
At a glance
- Originator Melior Discovery
- Developer Melior Pharmaceuticals, Inc.
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Irritable bowel syndrome
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Irritable-bowel-syndrome in USA
- 27 Jun 2008 Preclinical trials in Irritable bowel syndrome in USA (unspecified route)